Literature DB >> 20547399

Serotype-specific hyporesponsiveness to pneumococcal conjugate vaccine in infants carrying pneumococcus at the time of vaccination.

Merja Väkeväinen1, Anu Soininen, Marilla Lucero, Hanna Nohynek, Kari Auranen, P Helena Mäkelä, Gail Williams, Helena Käyhty.   

Abstract

OBJECTIVE: To determine whether pneumococcal carriage at the time of 11-valent pneumococcal conjugate vaccine (PCV-11) administration interferes with immune response in infants. STUDY
DESIGN: A total of 1111 Filipino infants recruited into an immunogenicity and carriage study, nested in an efficacy trial, received PCV-11 or saline solution placebo at 6, 10, and 14 weeks of age. Antibody concentrations to the most frequently carried vaccine serotypes 6B, 19F, and 23F were measured by enzyme immunoassay from sera obtained at 18 weeks and 9 months of age. Serotype-specific antibody concentration was compared between groups of children among PCV-11 recipients stratified according to their carriage status at 6 weeks of age.
RESULTS: Antibody concentrations to 6B, 19F, and 23F were significantly lower at 18 weeks and 9 months of age among children who were carriers of the specific serotype at 6 weeks of age than among non-carriers of the serotype. The hyporesponsiveness was specific to the carried serotype. The specific antibody concentrations induced by PCV-11 among carriers did not differ significantly from those in placebo recipients, whereas the differences were highly significant among noncarriers.
CONCLUSIONS: Pneumococcal carriage, prevalent in Filipino infants, interferes with serotype-specific immune response to primary series of PCV and has potential implications for immunization programs.
Copyright © 2010 Mosby, Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20547399     DOI: 10.1016/j.jpeds.2010.04.071

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  16 in total

1.  Impaired serotype-specific immune function following pneumococcal vaccination in infants with prior carriage.

Authors:  Paul V Licciardi; Fiona M Russell; Anne Balloch; Robert L Burton; Moon H Nahm; Gwendolyn Gilbert; Mimi L K Tang; Edward K Mulholland
Journal:  Vaccine       Date:  2014-03-06       Impact factor: 3.641

2.  Inferior quantitative and qualitative immune responses to pneumococcal conjugate vaccine in infants with nasopharyngeal colonization by Streptococcus pneumoniae during the primary series of immunization.

Authors:  Shabir A Madhi; Avy Violari; Keith P Klugman; Gina Lin; James A McIntyre; Anne von Gottberg; Patrick Jean-Philippe; Mark F Cotton; Peter Adrian
Journal:  Vaccine       Date:  2011-07-23       Impact factor: 3.641

Review 3.  Preventing pneumococcal disease in the elderly: recent advances in vaccines and implications for clinical practice.

Authors:  Angel Vila-Corcoles; Olga Ochoa-Gondar
Journal:  Drugs Aging       Date:  2013-05       Impact factor: 3.923

4.  An Adjuvant That Increases Protective Antibody Responses to Polysaccharide Antigens and Enables Recall Responses.

Authors:  James P Phipps; Karen M Haas
Journal:  J Infect Dis       Date:  2019-01-07       Impact factor: 5.226

5.  Cohort profile: The study of respiratory pathogens in Andean children.

Authors:  Carlos G Grijalva; Marie R Griffin; Kathryn M Edwards; John V Williams; Ana I Gil; Héctor Verastegui; Stella M Hartinger; Jorge E Vidal; Keith P Klugman; Claudio F Lanata
Journal:  Int J Epidemiol       Date:  2013-06-14       Impact factor: 7.196

6.  Capsule Switching and Antimicrobial Resistance Acquired during Repeated Streptococcus pneumoniae Pneumonia Episodes.

Authors:  Bin Chang; Akiyoshi Nariai; Tsuyoshi Sekizuka; Yukihiro Akeda; Makoto Kuroda; Kazunori Oishi; Makoto Ohnishi
Journal:  J Clin Microbiol       Date:  2015-08-12       Impact factor: 5.948

7.  Pneumococcal serotype-specific unresponsiveness in vaccinated child with cochlear implant.

Authors:  Elaine Stanford; Shamez Ladhani; Mary Slack; David Scott; Alec Fitzgerald-O'Connor; Pauline Waight; Rashmi Malkani; Ray Borrow
Journal:  Emerg Infect Dis       Date:  2012-06       Impact factor: 6.883

8.  Primary vaccination with the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in infants in Mali and Nigeria: a randomized controlled trial.

Authors:  Alassane Dicko; Olumuyiwa O Odusanya; Abdoulbaki I Diallo; Gaoussou Santara; Amadou Barry; Amagana Dolo; Aminata Diallo; Yetunde A Kuyinu; Omolara A Kehinde; Nancy François; Dorota Borys; Juan P Yarzabal; Marta Moreira; Lode Schuerman
Journal:  BMC Public Health       Date:  2011-11-23       Impact factor: 3.295

9.  Safety and immunogenicity of neonatal pneumococcal conjugate vaccination in Papua New Guinean children: a randomised controlled trial.

Authors:  William S Pomat; Anita H J van den Biggelaar; Suparat Phuanukoonnon; Jacinta Francis; Peter Jacoby; Peter M Siba; Michael P Alpers; John C Reeder; Patrick G Holt; Peter C Richmond; Deborah Lehmann
Journal:  PLoS One       Date:  2013-02-22       Impact factor: 3.240

10.  Pneumococcal polysaccharide abrogates conjugate-induced germinal center reaction and depletes antibody secreting cell pool, causing hyporesponsiveness.

Authors:  Stefania P Bjarnarson; Hreinn Benonisson; Giuseppe Del Giudice; Ingileif Jonsdottir
Journal:  PLoS One       Date:  2013-09-12       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.